Mustef (Dimethyl Fumarate)

Dimethyl fumarate activates the nuclear factor erythroid‑2‑related factor 2 (Nrf2) pathway, increasing antioxidant enzyme expression and modulating immune cell activity. This reduces oxidative stress and inflammatory cytokine production, contributing to its therapeutic effects in multiple sclerosis and psoriasis.

The dosage of Mustef is individualized by the prescribing clinician based on the patient’s condition, disease severity, and tolerability. The prescriber determines the appropriate starting dose and any titration schedule, following approved labeling and clinical guidelines.

The safety of dimethyl fumarate in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally reserved for situations where the potential benefit justifies any potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the Mustef product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other oral disease‑modifying therapies such as fingolimod or teriflunomide, dimethyl fumarate offers a distinct mechanism via Nrf2 activation and generally a favorable safety profile, though it is associated with flushing and lymphopenia. Choice of therapy depends on individual patient factors, efficacy, tolerability, and physician judgment.

Mustef should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Mustef is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water and should not be chewed, crushed, or split unless specifically instructed by a healthcare professional. Consistent daily intake supports optimal therapeutic effect.

The most serious risks include severe lymphopenia, which can predispose to opportunistic infections such as progressive multifocal leukoencephalopathy (PML), and rare cases of hepatic injury or severe allergic reactions. Regular monitoring of blood counts and liver function tests is recommended to detect these complications early.

Mustef is contraindicated in patients with known hypersensitivity to dimethyl fumarate or any excipients, those with active serious infections, and individuals with severe hepatic impairment. Caution is also advised for patients with a history of immunodeficiency or those receiving live vaccines. Consultation with a physician is required before initiating therapy.